A novel principle for partial agonism of liver X receptor ligands - Competitive recruitment of activators and repressors

被引:77
作者
Albers, M
Blume, B
Schlueter, T
Wright, MB
Kober, I
Kremoser, C
Deuschle, U
Koegl, M
机构
[1] PheneX Pharmaceut AG, D-67056 Ludwigshafen, Germany
[2] F Hoffmann La Roche & Cie AG, Dept Vasc & Metab Dis, CH-4070 Basel, Switzerland
关键词
D O I
10.1074/jbc.M510101200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
Partial, selective activation of nuclear receptors is a central issue in molecular endocrinology but only partly understood. Using LXRs as an example, we show here that purely agonistic ligands can be clearly and quantitatively differentiated from partial agonists by the cofactor interactions they induce. Although a pure agonist induces a conformation that is incompatible with the binding of repressors, partial agonists such as GW3965 induce a state where the interaction not only with coactivators, but also corepressors is clearly enhanced over the unliganded state. The activities of the natural ligand 22(R)-hydroxycholesterol and of a novel quinazolinone ligand, LN6500 can be further differentiated from GW3965 and T0901317 by their weaker induction of coactivator binding. Using biochemical and cell-based assays, we show that the natural ligand of LXR is a comparably weak partial agonist. As predicted, we find that a change in the coactivator to corepressor ratio in the cell will affect NCoR recruiting compounds more dramatically than NCoR-dissociating compounds. Our data show how competitive binding of coactivators and corepressors can explain the tissue-specific behavior of partial agonists and open up new routes to a rational design of partial agonists for LXRs.
引用
收藏
页码:4920 / 4930
页数:11
相关论文
共 50 条
[1]
Automated yeast two-hybrid screening for nuclear receptor-interacting proteins [J].
Albers, M ;
Kranz, H ;
Kober, I ;
Kaiser, C ;
Klink, M ;
Suckow, J ;
Kern, R ;
Koegl, M .
MOLECULAR & CELLULAR PROTEOMICS, 2005, 4 (02) :205-213
[2]
Ligands specify coactivator nuclear receptor (NR) box affinity for estrogen receptor subtypes [J].
Bramlett, KS ;
Wu, YF ;
Burris, TP .
MOLECULAR ENDOCRINOLOGY, 2001, 15 (06) :909-922
[3]
Chang CY, 1999, MOL CELL BIOL, V19, P8226
[4]
A TRANSCRIPTIONAL CO-REPRESSOR THAT INTERACTS WITH NUCLEAR HORMONE RECEPTORS [J].
CHEN, JD ;
EVANS, RM .
NATURE, 1995, 377 (6548) :454-457
[5]
The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse [J].
Chisholm, JW ;
Hong, J ;
Mills, SA ;
Lawn, RM .
JOURNAL OF LIPID RESEARCH, 2003, 44 (11) :2039-2048
[6]
Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].
Delmas, PD ;
Bjarnason, NH ;
Mitlak, BH ;
Ravoux, AC ;
Shah, AS ;
Huster, WJ ;
Draper, M ;
Christiansen, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647
[7]
A noncommercial dual luciferase enzyme assay system for reporter gene analysis [J].
Dyer, BW ;
Ferrer, FA ;
Klinedinst, DK ;
Rodriguez, R .
ANALYTICAL BIOCHEMISTRY, 2000, 282 (01) :158-161
[8]
The three-dimensional structure of the liver X receptor β reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands [J].
Färnegårdh, M ;
Bonn, T ;
Sun, S ;
Ljunggren, J ;
Ahola, H ;
Wilhelmsson, A ;
Gustafsson, JÅ ;
Carlquist, M .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (40) :38821-38828
[9]
Principles for modulation of the nuclear receptor superfamily [J].
Gronemeyer, H ;
Gustafsson, JÅ ;
Laudet, V .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (11) :950-964
[10]
Crystal structure of the human liver X receptor β ligand-binding domain in complex with a synthetic agonist [J].
Hoerer, S ;
Schmid, A ;
Heckel, A ;
Budzinski, RM ;
Nar, H .
JOURNAL OF MOLECULAR BIOLOGY, 2003, 334 (05) :853-861